Williams Jones Wealth Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.67K | Hold |
25,000
| – | – | ﹤0.01% | 538 |
|
|
2026
Q1 | $5.16K | Sell |
25,000
-2,000
| -7% | -$413 | ﹤0.01% | 506 |
|
|
2025
Q4 | $6.18K | Hold |
27,000
| – | – | ﹤0.01% | 508 |
|
|
2025
Q3 | $6.49K | Hold |
27,000
| – | – | ﹤0.01% | 500 |
|
|
2025
Q2 | $6.48K | Hold |
27,000
| – | – | ﹤0.01% | 500 |
|
|
2025
Q1 | $6.17K | Hold |
27,000
| – | – | ﹤0.01% | 492 |
|
|
2024
Q4 | $7.42K | Sell |
27,000
-8,000
| -23% | -$2.2K | ﹤0.01% | 494 |
|
|
2024
Q3 | $11.2K | Hold |
35,000
| – | – | ﹤0.01% | 532 |
|
|
2024
Q2 | $14.9K | Sell |
35,000
-5,000
| -13% | -$2.13K | ﹤0.01% | 510 |
|
|
2024
Q1 | $20.8K | Sell |
40,000
-4,000
| -9% | -$2.08K | ﹤0.01% | 535 |
|
|
2023
Q4 | $30.8K | Hold |
44,000
| – | – | ﹤0.01% | 530 |
|
|
2023
Q3 | $40K | Hold |
44,000
| – | – | ﹤0.01% | 533 |
|
|
2023
Q2 | $25K | Hold |
44,000
| – | – | ﹤0.01% | 516 |
|
|
2023
Q1 | $27.5K | Hold |
44,000
| – | – | ﹤0.01% | 551 |
|
|
2022
Q4 | $34.5K | Buy |
44,000
+5,000
| +13% | +$3.92K | ﹤0.01% | 546 |
|
|
2022
Q3 | $28K | Hold |
39,000
| – | – | ﹤0.01% | 556 |
|
|
2022
Q2 | $25K | Hold |
39,000
| – | – | ﹤0.01% | 558 |
|
|
2022
Q1 | $27K | Hold |
39,000
| – | – | ﹤0.01% | 518 |
|
|
2021
Q4 | $27K | Hold |
39,000
| – | – | ﹤0.01% | 491 |
|
|
2021
Q3 | $50K | Hold |
39,000
| – | – | ﹤0.01% | 477 |
|
|
2021
Q2 | $57K | Hold |
39,000
| – | – | ﹤0.01% | 485 |
|
|
2021
Q1 | $58K | Sell |
39,000
-11,000
| -22% | -$16.4K | ﹤0.01% | 481 |
|
|
2020
Q4 | $76K | Hold |
50,000
| – | – | ﹤0.01% | 457 |
|
|
2020
Q3 | $39K | Hold |
50,000
| – | – | ﹤0.01% | 427 |
|
|
2020
Q2 | $17K | Hold |
50,000
| – | – | ﹤0.01% | 413 |
|
|
2020
Q1 | $8K | Hold |
50,000
| – | – | ﹤0.01% | 381 |
|
|
2019
Q4 | $11K | Hold |
50,000
| – | – | ﹤0.01% | 441 |
|
|
2019
Q3 | $12K | Buy |
+50,000
| New | +$12K | ﹤0.01% | 424 |
|
Other funds holding NWBO
CFM
KFA
VWA
OCG
EFG
Williams Jones Wealth Management's NWBO Position: Q2 2026 in Review
Williams Jones Wealth Management held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q2 2026 at 25,000 shares worth $4.67K. The position accounts for ﹤0.01% of the portfolio, ranked #538.
Williams Jones Wealth Management first reported a position in NWBO in Q3 2019 and has held it in 28 quarters since. The position peaked at $76K in Q4 2020. 8 funds tracked by Wall St. Rank hold NWBO as of Q2 2026.
- Williams Jones Wealth Management held 25,000 shares of Northwest Biotherapeutics, Inc. Common stock worth $4.67K as of Q2 2026.
- Williams Jones Wealth Management left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q2 2026.
- Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of Williams Jones Wealth Management's portfolio in Q2 2026, its #538 holding.
- Williams Jones Wealth Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2019 and has held it in 28 quarters since.
- Williams Jones Wealth Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $76K in Q4 2020.
- 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2026.
Based on Williams Jones Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.